Neutralization assay for human group C rotaviruses using a reverse passive hemagglutination test for endpoint...

Area of Science:

• Virology
• Immunology
• Diagnostic Assay Development

Background:

• Human group C rotavirus (CHRV) is a significant cause of diarrheal disease.
• Existing methods for detecting CHRV neutralizing antibodies are limited.
• A sensitive and specific assay is needed for clinical and epidemiological surveillance.

Purpose of the Study:

• To develop and validate a novel neutralization assay for human group C rotavirus (CHRV).
• To evaluate the performance of the new assay in detecting seroconversion and determining seroprevalence.
• To establish a reliable method for assessing neutralizing antibodies against CHRV.

Main Methods:

• Development of a neutralization (N)-RPHA assay using reverse passive hemagglutination for endpoint determination.
• Incubation of serial twofold dilutions of sera with CHRV, followed by inoculation onto CaCo-2 cell monolayers.
• Determination of neutralization titer based on a fourfold or greater reduction in RPHA titer.

Main Results:

• The N-RPHA assay successfully demonstrated seroconversion in paired serum specimens from CHRV-infected patients.
• Seroprevalence of CHRV was found to be 26.8% by immunofluorescence and 25.5% by the N-RPHA test in Okayama Prefecture.
• The assay showed comparable results to immunofluorescence for seroprevalence determination.

Conclusions:

• The developed N-RPHA test is the first system for assaying neutralization antibodies against CHRV.
• This novel assay is applicable and effective in both clinical and epidemiological settings.
• The N-RPHA test provides a valuable tool for studying CHRV infections and immunity.